Name: Allie
License: http://creativecommons.org/licenses/by/2.1/jp/
Keywords: abbreviation,long form,database,lifescience,bioinformatics,biomedicine,webpage,webservice,MeSH,MEDLINE,PubMed

[Related PubMed/MEDLINE]
Total Number of Papers: 6440

[Display Entries]

>> all entries

[Entries Per Page]

per page

Page Control

Page: of

Abbreviation:	GLP-1 (>> Co-occurring Abbreviation)
Long Form:	glucagon-like peptide-1

Abbreviation Variation

Long Form Variation

Pair(Abbreviation/Long Form) Variation

			GLP-1 / glucagon-like peptide-1 (3411 times)
			GLP-1 / glucagon-like peptide 1 (1108 times)
			GLP-1 / Glucagon-like peptide-1 (1011 times)
			GLP-1 / Glucagon-like peptide 1 (328 times)
			GLP-1 / glucagon like peptide-1 (123 times)
			GLP1 / glucagon-like peptide 1 (60 times)
			GLP-1 / Glucagon-Like Peptide-1 (53 times)
			GLP-1 / Glucagon like peptide-1 (45 times)
			GLP-1 / glucagon-like-peptide-1 (45 times)
			GLP1 / glucagon-like peptide-1 (25 times)
			GLP-1 / glucagon like peptide 1 (25 times)
			GLP-1 / glucagonlike peptide-1 (24 times)
			GLP-1 / glucagon-like peptide-1(7-36)amide (15 times)
			GLP-1 / glucagon-like-peptide 1 (15 times)
			GLP1 / Glucagon-like peptide-1 (15 times)
			GLP1 / Glucagon-like peptide 1 (14 times)
			GLP-1 / Glucagon-like Peptide 1 (12 times)
			GLP-1 / glucagon-like peptide -1 (12 times)
			GLP-1 / glucagon-like peptide-1-(7-36) amide (12 times)
			GLP-1 / Glucagon Like Peptide-1 (11 times)
			GLP-1 / Glucagon-like peptide-1(7-36)amide (10 times)
			GLP-1 / Glucagon-like-peptide-1 (10 times)
			GLP-1 / Glucagon-like Peptide-1 (10 times)
			GLP-1 / glucagon-like peptide1 (9 times)
			GLP-1 / Glucagon like peptide 1 (8 times)
			GLP-1 / Glucagon-Like Peptide 1 (8 times)
			GLP-1 / glucagon-like polypeptide-1 (7 times)
			GLP-1 / glucagons-like peptide-1 (6 times)
			GLP-1 / glucagonlike peptide 1 (6 times)
			GLP-1 / Glucagonlike peptide-1 (5 times)
			GLP-1 / glucagon-like peptide-1(7-36) amide (5 times)
			GLP-1 / glucagon-like peptide-1-(7-36)-amide (5 times)
			GLP-1 / Glucagonlike peptide 1 (5 times)
			GLP-1 / glucagon-like peptide-1(7-36)-amide (4 times)
			GLP1 / glucagon like peptide 1 (4 times)
			GLP-1 / glucagon like-peptide 1 (4 times)
			GLP-1 / Glucagon-like peptide-1-(7-36) amide (3 times)
			GLP-1 / Glucagon-like-peptide 1 (3 times)
			GLP-1 / glucagon-like peptide 1(7-36) amide (3 times)
			GLP 1 / glucagon like peptide 1 (3 times)
			GLP 1 / glucagon-like peptide 1 (3 times)
			GLP-1 / glucagon-like peptide type 1 (3 times)
			GLP-1 / Glucagon-like peptide1 (3 times)
			GLP-1 / Glucagon like-peptide-1 (3 times)
			GLP-1 / glucagon like peptide -1 (3 times)
			GLP-1 / Glucagon-like peptide 1(7-36)amide (2 times)
			GLP-1 / Glucagon-like peptide-1 7-36 amide (2 times)
			GLP-1 / Glucagon-like peptide-1(7-36)-amide (2 times)
			GLP-1 / Glucagon-like peptide-1(7-36NH2) (2 times)
			GLP-1 / Glucagon-like peptide-1-(7-36)-amide (2 times)
			GLP-1 / Glucagon-like polypeptide 1 (2 times)
			GLP-1 / glucacon-like peptide-1 (2 times)
			GLP-1 / glucagon-like Peptide 1 (2 times)
			GLP-1 / glucagon-like peptide- 1 (2 times)
			GLP-1 / glucagon-like petide-1 (2 times)
			GLP-1 / glucagon-like polypeptide 1 (2 times)
			GLP-1 / glucagons like peptide-1 (2 times)
			GLP-1 / glucagons-like peptide 1 (2 times)
			GLP-1 / hormones--glucagon-like peptide-1 (2 times)
			GLP1 / Glucagon like peptide-1 (2 times)
			glp-1 / glucagon-like peptide-1 (2 times)
			GLP1 / glucagonlike peptide 1 (2 times)
			GLP- 1 / glucagon-like peptide-1 (2 times)
			GLP-1 / glucagone-like peptide-1 (2 times)
			GLP-1 / glucagon-like peptides 1 (2 times)
			GLP-1 / Glucagon like Peptide-1 (2 times)
			GLP-1 / glucose-like peptide 1 (2 times)
			GLP1 / Glucagon-like-peptide-1 (2 times)
			Glp1 / glucagon-like peptide 1 (2 times)
			GLP-1 / glucagon‑like peptide-1 (2 times)
			GLP1 / Glucagon Like Peptide 1 (2 times)
			GLP-1 / Glucagon-like pepetide-1 (2 times)
			GLP-1 / glucagon-like pepetide-1 (2 times)
			GLP-1 / glucagon-like peptide-17-36 amide (2 times)
			GLP-1 / glucagon-like peptide-1 analog (2 times)
			GLP-1 / glucagon-like preptide-1 (2 times)
			GLP-1 / Glucagon-like peptide-1 agonists (2 times)
			GLP-1 / Glucagon-like peptide -1 (1 time)
			GLP-1 / Glucagon-like peptide 1(7-36) amide (1 time)
			GLP-1 / Glucagon-like peptide 1-(7-36) amide (1 time)
			GLP-1 / Glucagon-like peptide- 1 (1 time)
			GLP-1 / Glucagon-like peptide-1(7-36) amide (1 time)
			GLP-1 / Glucagon-like peptide-1(7-36)amide/(7-37) (1 time)
			GLP-1 / Glucagon-like peptide-1(7-37) (1 time)
			GLP-1 / Glucagon-like peptide-1(7-37/36NH2) (1 time)
			GLP-1 / Glucagon-like peptide-1-(7---36) amide (1 time)
			GLP-1 / Glucagon-like peptide-1-(7-36) (1 time)
			GLP-1 / Glucagon-like-peptide-1(7-37) (1 time)
			GLP-1 / Glucon-like peptide-1 (1 time)
			GLP-1 / glucagon like peptide-1(7-36)amide (1 time)
			GLP-1 / glucagon-like peptide 1 (7-36)-amide (1 time)
			GLP-1 / glucagon-like peptide 1-(7-36) amide (1 time)
			GLP-1 / glucagon-like peptide 1-(7-36)-amide (1 time)
			GLP-1 / glucagon-like peptide 1-(7-36)amide (1 time)
			GLP-1 / glucagon-like peptide-1 (7-36) (1 time)
			GLP-1 / glucagon-like peptide-1 7-36 amide (1 time)
			GLP-1 / glucagon-like peptide-1((7-36)) amide (1 time)
			GLP-1 / glucagon-like peptide-1(7-36) (1 time)
			GLP-1 / glucagon-like peptide-1(7-36)NH2 (1 time)
			GLP-1 / glucagon-like peptide-1(7-37) (1 time)
			GLP-1 / glucagon-like peptide-1, 7-36 amide (1 time)
			GLP-1 / glucagon-like peptide-1-(7-36)amide (1 time)
			GLP-1 / glucagon-like peptide-1-(7-37) amide (1 time)
			GLP-1 / glucogen-like peptide 1 (1 time)
			GLP-1 / glucogen-like peptide-1 (1 time)
			GLP-1 / glucogon-like peptide-1 (1 time)
			GLP-1 / hormone--glucagon-like peptide-1 (1 time)
			Glp-1 / Glucagon like peptide-1 (1 time)
			Glp-1 / glucagon-like peptide 1 (1 time)
			GLP1 / glucagon like peptide-1 (1 time)
			GLP 1 / glucagon-like peptid 1 (1 time)
			GLP-1 / glucagon like peptid 1 (1 time)
			GLP-1 / glucagon-like peptide 1(7-36) (1 time)
			GLP-1 / Glucagon-like peptid-1 (1 time)
			GLP-1 / Glucagon like petide-1 (1 time)
			GLP-1 / Glucagon-like peptide type 1 (1 time)
			GLP-1 / glucagon like-peptide-1 (1 time)
			GLP-1 / glucagone like peptide-1 (1 time)
			GLP-1 / glucagonlike peptidase-1 (1 time)
			GLP-1 / glucagon-like polypetide-1 (1 time)
			Glp1 / Glucagon-like peptide-1 (1 time)
			GLP-1 / Glucagone like peptide-1 (1 time)
			GLP-1 / Glucose-like peptide 1 (1 time)
			Glp-1 / glucagon-like-peptide-1 (1 time)
			GLP-1 / Glucagon-Like-Peptide-1 (1 time)
			GLP-1 / glucogan-like peptide-1 (1 time)
			GLP-1 / non-glucagon-like peptide-1 (1 time)
			GLP-1 / glucagon- like peptide-1 (1 time)
			GLP-1 / glucagon-like peptide 1 (1 time)
			GLP-1 / coumarin-glucagon-like peptide-1 (1 time)
			Glp1 / glucagon-like peptide-1 (1 time)
			GLP-1 / glucagon-like peptide-17-36 (1 time)
			GLP-1 / Glucgon-Like-Peptide-1 (1 time)
			GLP- 1 / glucagon like peptide-1 (1 time)
			GLP-1 / glucagon-like Peptide-1 (1 time)
			GLP-1 / glucagon-like peptid-1 (1 time)
			GLP 1 / glucagon-like peptide-1 (1 time)
			GLP-1 / glucagon-like peptides-1 (1 time)
			GLP-1 / Glucogan-like peptide 1 (1 time)
			GLP-1 / glucagon likes peptide 1 (1 time)
			GLP-1 / Glucagon Like Peptide 1 (1 time)
			GLP-1 / glucagon-like peptide type-1 (1 time)
			GLP-1 / glucagon-like peptide-1 analogue (1 time)
			GLP-1 / Glukagon-like-peptide-1 (1 time)
			GLP-1 / Glucagone like peptide 1 (1 time)
			GLP-1 / glucagon-like peptide-1 analogs (1 time)
			GLP- 1 / glucagon- like peptide- 1 (1 time)
			GLP1 / Glucagon-Like Peptide-1 (1 time)
			GLP-1 / Glucagon-like peptide-1 amide (1 time)
			Glp-1 / glucagon-like peptide-1 (1 time)
			GLP-1 / Glucagon-likepeptide1 (1 time)
			GLP-1 / glucose like peptide 1 (1 time)
			GLP-1 / aglucagon-like peptide-1 (1 time)
			GLP-1 / Glucose Like peptide-1 (1 time)
			GLP-1 / glycogen-like peptide-1 (1 time)
			GLP1 / Glucagon-Like Peptide 1 (1 time)
			GLP-1 / Glucagon- like peptide-1 (1 time)
			GLP-1 / glucacon-like peptide 1 (1 time)
			GLP-1 / giucagon-like peptide-1 (1 time)
			GLP-1 / 2-Glucagon-Like Peptide-1 (1 time)
			GLP-1 / Glucagon Like- Peptide-1 (1 time)
			GLP-1 / hormones-glucagon-like peptide 1 (1 time)
			GLP-1 / gluacagon-like peptide-1 (1 time)
			GLP-1 / Glucagon-like peptides-1 (1 time)
			GLP-1 / ofglucagon-like peptide 1 (1 time)
			GLP-1 / glucagon-like peptide-1 analogues (1 time)
			GLP1 / Glucagon like peptide 1 (1 time)
			GLP-1 / Glucagon-like pepide-1 (1 time)
			GLP-1 / glucagon like peptide - 1 (1 time)
			GLP-1 / glucagon-like peptide 1 (1 time)
			GLP-1 / glucagon like pepetide-1 (1 time)
			GLP-1 / glucagon-like peptide (1 time)
			GLP-1 / glucagon-like peptidase 1 (1 time)
			GLP1 / Glucagon Like Peptide-1 (1 time)
			GLP1 / glucagon-like-peptide-1 (1 time)

No.	Year	Title	Co-occurring Abbreviation
1	2020	(EX-4)2-Fc, an effective long-acting GLP-1 receptor agonist, reduces obesity-related inflammation by inhibiting leptin expression.	DIO, MAPK, NF-kappaB, T2D
2	2020	2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).	ADA, CKD, CVD, EASD, HHF, MACE, SGLT2
3	2020	2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).	ADA, CKD, CVD, EASD, HHF, MACE, SGLT2
4	2020	A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity.	BMI, OGTT
5	2020	A Comparison of Gastric and Jejunal Feeding in Hypercatabolism Associated With Hypothalamic AMPK-Autophagy-POMC in Endotoxemic Rats.	AMPK, EN, GF, GHS-R1alpha, JF, LPS, POMC
6	2020	A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice.	AD, GCG, LTP, Oxm, T2DM
7	2020	A free-energy landscape for the glucagon-like peptide 1 receptor GLP1R.	GPCRs
8	2020	A GLP-1 Analog Liraglutide Reduces Intimal Hyperplasia After Coronary Stent Implantation via Regulation of Glycemic Variability and NLRP3 Inflammasome/IL-10 Signaling in Diabetic Swine.	DM, GMS, HG, L group, LA, NIA, NIT, SDs
9	2020	A GLP-2 Analogue Protects SH-SY5Y and Neuro-2a Cells Against Mitochondrial Damage, Autophagy Impairments and Apoptosis in a Parkinson Model.	GLP-2, PD, TEM
10	2020	A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?	NAFLD, SGLT2, T2D
11	2020	A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice.	DIO, GCG, NASH, OXM, PEG
12	2020	A novel mouse model of glucagon-like peptide-1 receptor expression: A look at the brain.	CNS, mApple
13	2020	A novel thrombin-based triagonist with diabetes-protective and weight-lowering potential.	GIP, OGTT
14	2020	A Physiologically-Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP-1 and GIP and the DPP4 Inhibitor Sitagliptin.	DPP4, GIP, NEP, PB
15	2020	A Pilot Study Examining the Effects of GLP-1 Receptor Blockade Using Exendin-(9,39) on Gastric Emptying and Caloric Intake in Subjects With and Without Bariatric Surgery.	---
16	2020	A Protein/Lipid Preload Attenuates Glucose-Induced Endothelial Dysfunction in Individuals with Abnormal Glucose Tolerance.	GIP, IGT, OGTTs, RHI, T2D
17	2020	A Review of Recent Findings on Meal Sequence: An Attractive Dietary Approach to Prevention and Management of Type 2 Diabetes.	GIP
18	2020	A Review of the Renoprotective Effects of Novel Antidiabetic Agents.	DPP-4, SGLT2
19	2020	A systematic review and meta-analysis of medium-chain triglycerides effects on acute satiety and food intake.	GIP, LCT, MCT, PP, PYY
20	2020	Abdominal aortic aneurysm: a review on the role of oral antidiabetic drugs.	AAA, DPP-4, SGLT2, SU, TZD
21	2020	Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats.	---
22	2020	Activation of the GLP-1 receptor by a non-peptidic agonist.	---
23	2020	Activation of Transient Receptor Potential Channel Vanilloid 4 by DPP-4 (Dipeptidyl Peptidase-4) Inhibitor Vildagliptin Protects Against Diabetic Endothelial Dysfunction.	AMPK, DPP-4, SIRT1, TRPV4
24	2020	Acute effects of an isocaloric macronutrient-matched breakfast meal containing almonds on glycemic, hormonal, and appetite responses in men with type 2 diabetes: a randomized crossover study.	T2D
25	2020	Acute effects of sitagliptin on progenitor cells and soluble mediators in newly diagnosed type 2 diabetes.	EPCs, ET-1, NO, SDF-1alpha
26	2020	Acute exposure to a hot ambient temperature reduces energy intake but does not affect gut hormones in men during rest.	PYY
27	2020	Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes.	DPP4, SGLT2
28	2020	Albumin-binding domain extends half-life of glucagon-like peptide-1.	ABD, HSA, T2DM
29	2020	Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1.	AUD, Ex-4
30	2020	Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function.	---
31	2020	Alterations in Enteroendocrine Hormones After Total Pancreatectomy With Islet Autotransplantation.	PP, PYY, TPIAT
32	2020	Alterations in pancreatic islet cell function in response to small bowel resection.	SBR
33	2020	Amelioration of diet-induced metabolic syndrome and fatty liver with sitagliptin via regulation of adipose tissue inflammation and hepatic Adiponectin/AMPK levels in mice.	ACC, AMPK, FSI
34	2020	Amino Acids in Health and Endocrine Function.	IGF-1
35	2020	An Almond-Based Low Carbohydrate Diet Improves Depression and Glycometabolism in Patients with Type 2 Diabetes through Modulating Gut Microbiota and GLP-1: A Randomized Controlled Trial.	a-LCD, LCD, LFD
36	2020	An orally available hypoglycaemic peptide taken up by caveolae transcytosis displays improved hypoglycaemic effects and body weight control in db/db mice.	OHP2
37	2020	Anagliptin stimulates osteoblastic cell differentiation and mineralization.	ALP, OCN, OPN
38	2020	Anagliptin, a dipeptidyl peptidase-4 inhibitor, improved bladder function and hemodynamics in rats with bilateral internal iliac artery ligation.	Ana, DPP-4, ICIs, LIG
39	2020	Antagonistic interaction between central glucagon-like Peptide-1 and oxytocin on diet-induced obesity mice.	DIO, OXT
40	2020	Anti-hyperglycemic activity of myricetin, through inhibition of DPP-4 and enhanced GLP-1 levels, is attenuated by co-ingestion with lectin-rich protein.	DC, DPP-4, HP, Myr, NLRP3, STZ
41	2020	Antidiabetic drug therapy alleviates type 1 diabetes in mice by promoting pancreatic alpha-cell transdifferentiation.	GIP, SGLT2
42	2020	Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map.	CIs, DPP4, NAFLD, SGLT2, SMDs, WMDs
43	2020	Antidiabetic effects of selenium-enriched Bifidobacterium longum DD98 in type 2 diabetes model of mice.	FBG, Se-B. longum DD98, STZ
44	2020	Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis.	HCC, NAFLD, NASH, SGLT2, T2D
45	2020	Appetite control: hormones or diet strategies?	PYY
46	2020	Appetite-regulating hormones and anthropometric indicators of infants according to the type of feeding.	FBF, HMS, PBF
47	2020	Appetite-Regulating Hormones in Human Milk: A Plausible Biological Factor for Obesity Risk Reduction?	PYY
48	2020	Assessing the Continuation of Glucagon-Like Peptide-1 Receptor Agonists When Weight and HBA1C Are Not Reduced.	---
49	2020	Assessing the effect of starch digestion characteristics on ileal brake activation in broiler chickens.	PYY, SCFA, WS
50	2020	Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.	HRs, SGLT2
51	2020	Assessment of antidiabetic potential and phytochemical profiling of Rhazya stricta root extracts.	DPP-IV
52	2020	Assessment of Second-Generation Diabetes Medication Initiation Among Medicare Enrollees From 2007 to 2015.	DPP-4, SGLT2
53	2020	Association between allelic variants in the glucagon-like peptide 1 and cholecystokinin receptor genes with gastric emptying and glucose tolerance.	GE, SNPs
54	2020	Association of a glucagon-like peptide-1 receptor gene variant with glucose response to a mixed meal.	DPP-4, GLP-1R
55	2020	Bariatric surgery reveals a gut-restricted TGR5 agonist with anti-diabetic effects.	CA7S, GI, TGR5
56	2020	Beneficial Effects of Glucagon-Like Peptide-1 (GLP-1) in Diabetes-Induced Retinal Abnormalities: Involvement of Oxidative Stress.	---
57	2020	Bifidobacterium from breastfed infant faeces prevent high-fat-diet-induced glucose tolerance impairment, mediated by the modulation of glucose intake and the incretin hormone secretion axis.	HFD
58	2020	Bile acid treatment and FXR agonism lower postprandial lipemia in mice.	DCA, FXR, TA, TGR5
59	2020	Binge-like palatable food intake in rats reduces preproglucagon in the nucleus tractus solitarius.	NTS, PPG
60	2020	Brain Endothelial Cells Regulate Glucagon-Like Peptide 1 Entry Into the Brain via a Receptor-Mediated Process.	---
61	2020	Brain insulin resistance: role in neurodegenerative disease and potential for targeting.	GIP
62	2020	Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics.	AD, BBB, CNS, GIP, IRAs, PD
63	2020	Butyric acid normalizes hyperglycemia caused by the tacrolimus-induced gut microbiota.	PYY
64	2020	Cacao polyphenols regulate the circadian clock gene expression and through glucagon-like peptide-1 secretion.	CLPr
65	2020	Caloric restriction alters the hormonal profile and testicular metabolome, resulting in alterations of sperm head morphology.	CR
66	2020	Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?	---
67	2020	Capsaicin improves glucose homeostasis by enhancing glucagon-like peptide-1 secretion through the regulation of bile acid metabolism via the remodeling of the gut microbiota in male mice.	BA, CAP, HFD, LCA, TGR5
68	2020	Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-alpha.	caECs, CASMCs, MTPalpha, NEP-generated, sAC-dependent
69	2020	Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association.	CKD, SGLT2, T2D
70	2020	Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes.	GLP-1RAs, T2DM
71	2020	CCK-1 and CCK-2 receptor agonism do not stimulate GLP-1 and neurotensin secretion in the isolated perfused rat small intestine or GLP-1 and PYY secretion in the rat colon.	CCK, GIP, PYY, VIP
72	2020	Cerebral effects of GLP-1 receptor blockade before and after Roux-en-Y Gastric Bypass in obese women: a proof-of-concept resting-state fMRI study.	RYGB
73	2020	Changes in incidence of severe hypoglycaemia in people with type 2 diabetes from 2006 to 2016: analysis based on health insurance data in Germany considering the anti-hyperglycaemic medication.	ATC, DPP-4, OR, SGLT2
74	2020	Childhood trauma and glucose metabolism in patients with first-episode psychosis.	BMI, CT, FEP, GIP, PAI-1, SLEs
75	2020	Chitooligosaccharides Modulate Glucose-Lipid Metabolism by Suppressing SMYD3 Pathways and Regulating Gut Microflora.	COS, CYP7A1, HMGCR, SMYD3, T2DM
76	2020	Choice of Lipid Emulsion Determines Inflammation of the Gut-Liver Axis, Incretin Profile, and Insulin Signaling in a Murine Model of Total Parenteral Nutrition.	JVC, TPN
77	2020	Chronic high fat diet impairs glucagon like peptide-1 sensitivity in vagal afferents.	Ex-4, HFF, LFF, NTS
78	2020	Chronic n-3 fatty acid intake enhances insulin response to oral glucose and elevates GLP-1 in high-fat diet-fed obese mice.	cHF, OGTT, PUFA
79	2020	Circadian GLP-1 Secretion in Mice is Dependent on the Intestinal Microbiome for Maintenance of Diurnal Metabolic Homeostasis.	---
80	2020	Circulating glucagon-like peptide-1 level in patients with liver cirrhosis.	UKELD
81	2020	Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes.	AGEs, BMI, i.v, OGTT, sRAGE
82	2020	Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy.	GIP, PYY, T2D
83	2020	Combination of Lorcaserin and GLP-1/glucagon Coagonist Improves Metabolic Dysfunction in Diet Induced-obese Mice.	DIO
84	2020	Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes.	CV, SGLT2
85	2020	Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?	CKD, NAFLD, NASH, SGLT2, SKLT, T2D
86	2020	Comparable Postprandial Amino Acid and Gastrointestinal Hormone Responses to Beef Steak Cooked Using Different Methods: A Randomised Crossover Trial.	aa, GI, GIP, PF, SV, UPLC
87	2020	Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data.	---
88	2020	Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.	alpha-GIs, DPP-4, HOMA-beta, PIR, SGLT2
89	2020	Conservation of glucagon like peptide-1 level with liraglutide and linagilptin protects the kidney against angiotensin II-induced tissue fibrosis in rats.	Ang II
90	2020	Consuming decaffeinated coffee with milk and sugar added before a high-glycaemic index meal improves postprandial glycaemic and insulinaemic responses in healthy adults.	GI
91	2020	Controlled Release of Pyrimidine Compound Using Polymeric Coated ZIF-8 Metal-Organic Framework as Glucagon-Like Peptide-1 Receptor Agonist Carrier.	MOFs
92	2020	Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus.	AEs, BMI, NHS, QALYs, SA, T2DM, UKPDS
93	2020	Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review.	ACEI, ARBs, NSAIDs, SYRCLE
94	2020	Cyclocarya paliurus polysaccharides alleviate type 2 diabetic symptoms by modulating gut microbiota and short-chain fatty acids.	CCPP, PYY, SCFAs, T2DM
95	2020	Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice.	SGLT2
96	2020	Degradation of the Incretin Hormone Glucagon-Like Peptide-1 (GLP-1) by Enterococcus faecalis Metalloprotease GelE.	---
97	2020	Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes.	CI, DPP4, IRR
98	2020	Diabetes: From Research to Clinical Practice.	CGM, CSII, SGLT2
99	2020	Dietary Cyanidin-3-Glucoside Attenuates High-Fat-Diet-Induced Body-Weight Gain and Impairment of Glucose Tolerance in Mice via Effects on the Hepatic Hormone FGF21.	ABs, Cy3G, Exp, FGF21, HFD, LFD
100	2020	Dietary macronutrient regulation of acyl and desacyl ghrelin concentrations in children with Prader-Willi syndrome (PWS).	AG, DAG, HC, HP-LC, HP-LF, PWS, PYY

A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : GLP-1 / glucagon-like peptide-1